Accord Logo

Intended for UK patients and members of the public

SmPC - Zipamol™ PLUS 8 mg/500 mg Effervescent Tablets: Change history

  • Description of update: To update sections 4.4, 4.5 and 4.9 of the SPC to bring in line with the Reference product, Co-codamol 8/500 Effervescent Tablets - PL 17780/0072 (MAH: Zentiva Pharma UK Limited. Consequently, the leaflet (PIL) is being updated.

    SmPC Sections updated: 4.4, 4.5, 4.9 and 10.

    • Changes: (Updated: 17 Apr 2024)

      Description of update: To update sections 4.4, 4.5 and 4.9 of the SPC to bring in line with the Reference product, Co-codamol 8/500 Effervescent Tablets - PL 17780/0072 (MAH: Zentiva Pharma UK Limited. Consequently, the leaflet (PIL) is being updated.

      SmPC Sections updated: 4.4, 4.5, 4.9 and 10.

    • Changes: (Updated: 10 Apr 2024)

      Description of update: To register the additional pack size of 24s in blister packs for Co-codamol 8mg/500mg effervescent tablets, Zipamol PLUS 8mg/500mg effervescent tablets and for Own Label Supplier Boots for Paracetamol & Codeine 500mg/8mg Effervescent Tablets with consequential new cartons pack size 24s and updates to leaflets. Consequential updates are made to SmPC section 6.5. The current approved foils will also be used for the 24s pack. Minor editorial corrections are also made to the existing pack size 32s cartons for Co-codamol 8mg/500mg effervescent tablets and Zipamol PLUS 8mg/500mg effervescent tablets and leaflets.

      SmPC Sections updated: 6.5 & 10.

    • Changes: (Updated: 15 Aug 2023)

      Description of update: To add Boots UK Limited, 1, Thane Road West, Nottingham, NG2 3AA, United Kingdom as OLS (using own label and leaflet) with product name ‘Paracetamol & Codeine 500mg/8mg Effervescent Tablets’. Therefore, the SmPC (section 1) is updated.

      SmPC section(s) updated – 1 and 10.

    • Changes: (Updated: 19 May 2023)

      Variation Description:   1) To update section 4.4 of the SmPC and section 2 of the PIL  to include cautionary warning to patients with myasthenia gravis. 

      2) To update section 4.4 of the SmPC and section 2 of the PIL to highlight the drug interaction between co-codamol and antidepressants.

      3) Typographical amendments to the PIL.

      SmPC sections updated- 4.4 and 10.

    • Changes: (Updated: 03 Jan 2023)

      Variation approval date from MHRA updated from 17/05/2022 to 14/12/2022.

    • Changes: (Updated: 20 Dec 2022)

      Variation Description:

      To update sections 4.3, 4.4, 4.6, 4.8, 4.9, 5.1, 5.3 and 6.1 of the SmPC in line with reference product Co-codamol 8/500 Effervescent Tablets.

      Additionally, the excipient warnings for sodium and sorbitol in SmPC section 4.4 and PIL section 2, have been updated in line with the latest EC guidelines on excipients (EMA/CHMP/302620/2017) and corresponding PRAC recommendations.

      SmPC section 6.1. and PIL section 6 have been updated to remove the word ‘anhydrous’ in line with the EP 9th edition, hydrates list.

       SmPC sections updated – 4.3, 4.4, 4.6, 4.8, 4.9, 5.1, 5.3, 6.1 and 10

    • Changes: (Updated: 20 Dec 2022)

      Variation Description:

      To update sections 4.3, 4.4, 4.6, 4.8, 4.9, 5.1, 5.3 and 6.1 of the SmPC in line with reference product Co-codamol 8/500 Effervescent Tablets.

      Additionally, the excipient warnings for sodium and sorbitol in SmPC section 4.4 and PIL section 2, have been updated in line with the latest EC guidelines on excipients (EMA/CHMP/302620/2017) and corresponding PRAC recommendations.

      SmPC section 6.1. and PIL section 6 have been updated to remove the word ‘anhydrous’ in line with the EP 9th edition, hydrates list.

       SmPC sections updated – 4.3, 4.4, 4.6, 4.8, 4.9, 5.1, 5.3, 6.1 and 10

    • Changes: (Updated: 22 Sep 2022)

      initial upload

    View product information as a: